Published in Vaccine Weekly, June 1st, 2005
ZOSTAVAX is an investigational vaccine for the prevention of herpes zoster, commonly known as "shingles;" prevention of postherpetic neuralgia (PHN), the persistent, long-term nerve pain that is the most common complication of shingles; and the reduction of acute and chronic shingles-associated pain in adults.
Merck submitted the application for ZOSTAVAX on April 25. Within the next 60 days, the FDA will determine whether it will accept for review Merck's application as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly